OR06-5 Fezolinetant for Treatment of Moderate-to-severe Vasomotor Symptoms Associated with Menopause: Results from a 52-week Study (Skylight 2)

BACKGROUND: SKYLIGHT 2 (NCT04003142) investigated safety and efficacy of fezolinetant (a neurokinin-3 receptor antagonist) on frequency and severity of moderate-to-severe vasomotor symptoms (VMS) and sleep disturbance. In this analysis, persistence of fezolinetant efficacy was investigated over 52 w...

Descripción completa

Detalles Bibliográficos
Autores principales: English, Marci, Franklin, Catherine, Johnson, Kimball, Lee, Misun, Nappi, Rossella E, Ottery, Faith, Santoro, Nanette, Shapiro, Marla, Stute, Petra, Thurston, Rebecca C, Wolfman, Wendy, Neal-Perry, Genevieve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Reproductive Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625322/
http://dx.doi.org/10.1210/jendso/bvac150.1403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625322/
http://dx.doi.org/10.1210/jendso/bvac150.1403

Ejemplares similares